518 related articles for article (PubMed ID: 20451868)
1. The Alzheimer's disease neuroimaging initiative: progress report and future plans.
Weiner MW; Aisen PS; Jack CR; Jagust WJ; Trojanowski JQ; Shaw L; Saykin AJ; Morris JC; Cairns N; Beckett LA; Toga A; Green R; Walter S; Soares H; Snyder P; Siemers E; Potter W; Cole PE; Schmidt M;
Alzheimers Dement; 2010 May; 6(3):202-11.e7. PubMed ID: 20451868
[TBL] [Abstract][Full Text] [Related]
2. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
[TBL] [Abstract][Full Text] [Related]
3. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
[TBL] [Abstract][Full Text] [Related]
4. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
[TBL] [Abstract][Full Text] [Related]
5. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.
Weigand SD; Vemuri P; Wiste HJ; Senjem ML; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Jack CR;
Alzheimers Dement; 2011 Mar; 7(2):133-41. PubMed ID: 21282074
[TBL] [Abstract][Full Text] [Related]
6. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
8. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
[TBL] [Abstract][Full Text] [Related]
9. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
10. Integrating ADNI results into Alzheimer's disease drug development programs.
Cummings JL
Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
12. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.
Toledo JB; Weiner MW; Wolk DA; Da X; Chen K; Arnold SE; Jagust W; Jack C; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ;
Acta Neuropathol Commun; 2014 Mar; 2():26. PubMed ID: 24602322
[TBL] [Abstract][Full Text] [Related]
13. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
14. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
[TBL] [Abstract][Full Text] [Related]
15. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
16. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.
Aisen PS; Petersen RC; Donohue MC; Gamst A; Raman R; Thomas RG; Walter S; Trojanowski JQ; Shaw LM; Beckett LA; Jack CR; Jagust W; Toga AW; Saykin AJ; Morris JC; Green RC; Weiner MW;
Alzheimers Dement; 2010 May; 6(3):239-46. PubMed ID: 20451872
[TBL] [Abstract][Full Text] [Related]
17. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.
Weiner MW; Veitch DP
Alzheimers Dement; 2015 Jul; 11(7):730-3. PubMed ID: 26194308
[TBL] [Abstract][Full Text] [Related]
18. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
20. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
